PL431139A1 - Kompozycja farmaceutyczna bimatoprostu i tymololu - Google Patents
Kompozycja farmaceutyczna bimatoprostu i tymololuInfo
- Publication number
- PL431139A1 PL431139A1 PL431139A PL43113919A PL431139A1 PL 431139 A1 PL431139 A1 PL 431139A1 PL 431139 A PL431139 A PL 431139A PL 43113919 A PL43113919 A PL 43113919A PL 431139 A1 PL431139 A1 PL 431139A1
- Authority
- PL
- Poland
- Prior art keywords
- bimatoprost
- timolol
- pharmaceutical composition
- application
- preservative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Przedmiotem zgłoszenia jest kompozycja farmaceutyczna bimatoprostu i tymololu, do stosowania w celu obniżenia ciśnienia wewnątrzgałkowego u pacjenta, która stanowi niezawierający konserwantów sterylny roztwór wodny o następującej recepturze: 0,03% wag. bimatoprostu, 0,5% wag. tymololu, 0,358% wag. dodekahydratu dwuzasadowego fosforanu sodu, 0,014% wag. monohydratu kwasu cytrynowego, 0,72% wag. chlorku sodu, woda z pH na poziomie 7,3. Zgłoszenie obejmuje także sposób otrzymywania powyższej kompozycji.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL431139A PL431139A1 (pl) | 2019-09-13 | 2019-09-13 | Kompozycja farmaceutyczna bimatoprostu i tymololu |
PCT/PL2020/050066 WO2021049963A1 (en) | 2019-09-13 | 2020-09-13 | Pharmaceutical composition of bimatoprost and timolol |
EP20797887.5A EP4027977A1 (en) | 2019-09-13 | 2020-09-13 | Pharmaceutical composition of bimatoprost and timolol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL431139A PL431139A1 (pl) | 2019-09-13 | 2019-09-13 | Kompozycja farmaceutyczna bimatoprostu i tymololu |
Publications (1)
Publication Number | Publication Date |
---|---|
PL431139A1 true PL431139A1 (pl) | 2021-03-22 |
Family
ID=73030187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL431139A PL431139A1 (pl) | 2019-09-13 | 2019-09-13 | Kompozycja farmaceutyczna bimatoprostu i tymololu |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4027977A1 (pl) |
PL (1) | PL431139A1 (pl) |
WO (1) | WO2021049963A1 (pl) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024003078A1 (en) * | 2022-06-27 | 2024-01-04 | Warszawskie Zaklady Farmaceutyczne Polfa Sa | Preservative-free ophthalmic composition comprising a prostaglandin analogue |
CN115998888A (zh) * | 2023-01-16 | 2023-04-25 | 广州楷石医药有限公司 | 用于治疗青光眼或高眼压症的药物组合物及其用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011282681B2 (en) * | 2010-07-29 | 2015-07-30 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
GR1009006B (el) * | 2016-04-01 | 2017-04-04 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χρηση περιεχον βιματοπροστη και τιμολολη |
CN108236721A (zh) * | 2016-12-26 | 2018-07-03 | 上海创诺医药集团有限公司 | 一种稳定的贝伐单抗制剂 |
-
2019
- 2019-09-13 PL PL431139A patent/PL431139A1/pl unknown
-
2020
- 2020-09-13 WO PCT/PL2020/050066 patent/WO2021049963A1/en unknown
- 2020-09-13 EP EP20797887.5A patent/EP4027977A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021049963A1 (en) | 2021-03-18 |
EP4027977A1 (en) | 2022-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200998T1 (hr) | Postupak i sastav za liječenje okularne hipertenzije i glaukoma | |
ES2244831T5 (es) | Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica | |
TWI399207B (zh) | 改良之比馬前列素(bimatoprost)眼用溶液 | |
RU2013107744A (ru) | Растворы биматопроста и тимолола, не содержащие консервантов | |
JP5568246B2 (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用点眼剤 | |
NZ609719A (en) | Pharmaceutical composition | |
PL431139A1 (pl) | Kompozycja farmaceutyczna bimatoprostu i tymololu | |
KR890011823A (ko) | 벤조일 페닐아세트산 유도체 약제 조성물 | |
BRPI0610901A2 (pt) | mÉtodo de uso de uma soluÇço aquosa de potencial oxi-redutivo em aplicaÇÕes dentais | |
BRPI0714808A2 (pt) | mÉtodos e composiÇÕes para o tratamento e a prevenÇço de infecÇÕes | |
GB1287673A (en) | Injectable compositions | |
HUP0203773A2 (hu) | Epinastintartalmú oldatok | |
JP2013535472A5 (pl) | ||
ITRM20090102U1 (it) | Ialuvit preparato per la stabilizzazione del film lacrimale, la cicatrizzazione corneale e il ripristino del contenuto salino della lacrima e osmoprotezione. | |
AR043536A1 (es) | Composicion farmaceutica que comprende acido 5-metil-2-(2´-cloro-6´-fluoroanilino)fenilacetico | |
AR111166A1 (es) | Uso intradialítico de nitrito de sodio | |
CA2535533A1 (en) | Aqueous pharmaceutical solution comprising oxymetazoline and/or xylometazoline | |
BR112021025558A2 (pt) | Formulação estável de cetrorelix e processo para a preparação de uma formulação estável | |
UY38055A (es) | Composiciones oftálmicas de compuestos de bencimidazol para uso unico diario | |
WO2012074237A3 (ko) | 도르졸라미드, 티몰롤 및 브리모니딘을 포함하는 안과용 액제 조성물 | |
DE602005001918D1 (de) | S-tenatoprazolnatrium-monohydrat-salz und dessen verwendung in form eines protonenpumpenhemmers | |
JP2022186861A5 (pl) | ||
NZ591213A (en) | A formulation of canfosfamide consisting of 50 mg/mL canfosfamide hydrochloride in aqueous sodium citrate buffer | |
CO6270205A2 (es) | Formulacion que contiene un compuesto inhibidor de quinasa dependiente de ciclina y metodo para tratar tumores utilizando el mismo | |
DE60024875D1 (de) | Perfusionslösung zusammensetzungen für ophthalmische verfahren |